Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    U.S. Hotel Construction Shrinks Again for Ninth Consecutive Month

    October 23, 2025

    AWS Restores Services After Major Cloud Outage Disrupts Users Globally

    October 22, 2025

    Palantir, Snowflake’s Big AI Data Partnership Fails to Win Over Investors

    October 17, 2025
    Facebook X (Twitter) Instagram LinkedIn
    • About Us
    • Press Release
    Thursday, October 23
    Facebook X (Twitter) LinkedIn Instagram
    Business Leaders Review: Best Business Magazine and News OnlineBusiness Leaders Review: Best Business Magazine and News Online
    • Home
    • Magazines
    • Featured Leaders
    • Technology
      • Big Data
      • Artificial Intelligence
      • Robotics
      • Cloud
      • Cyber Security
      • Storage
      • IoT
      • Blockchain
      • Data Analytics
    • Industry
      • Banking & Finance
      • Construction
      • Digital Marketing
      • Economy
      • Education
      • EV Industry
      • Food & Beverage
      • Healthcare
      • Legal
      • Manufacturing
      • Mining & Metals
      • Pharmaceutical
    • Testimonials
    • Events
    • Blogs
    • Awards
    • Our Clients
    Business Leaders Review: Best Business Magazine and News OnlineBusiness Leaders Review: Best Business Magazine and News Online
    Home » US: FDA approves high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm) injection
    Biotechnology

    US: FDA approves high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm) injection

    By Business Leaders ReviewMay 3, 2024
    US: FDA approves high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm) injection

    The high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), an interchangeable biosimilar to Humira (adalimumab) developed by German family-owned pharmaceutical giant Boehringer Ingelheim, has been approved by the US Food and Drug Administration (FDA) for the treatment of certain chronic inflammatory conditions.

    “With this FDA approval, we are now able to offer both high- and low-concentration, citrate-free formulations of Cyltezo, further expanding treatment access for patients living with certain chronic inflammatory diseases,” said Stephen Pagnotta, Executive Director and Biosimilar Commercial Lead at Boehringer Ingelheim. “Many patients are treated with high-concentration adalimumab formulations, and we are excited to add this new option to our approved citrate-free Cyltezo and Adalimumab-adbm offerings.”

    Cyltezo’s low-concentration, citrate-free formulation was first authorized in August 2017.

    Extensive data, including results from the VOLTAIRE-HCLF experiment (ClinicalTrials.gov Identifier: NCT05203289), were used to support the FDA clearance. After a single subcutaneous injection, the pharmacokinetics of Cyltezo’s high-concentration and low-concentration formulations were evaluated in this study.

    Roughly 80% of prescriptions for adalimumab are for high-concentration medication. This approval, which comes after Hadlima, Hyrimoz, Yuflyma, and Simlandi, is the sixth for a high-concentration adalimumab. Cyltezo, Hadlima, and Hyrimoz are the only products with a high-concentration formulation that are also available in a low-concentration formulation.

    “Biologics and biosimilars are a crucial treatment option for many living with psoriatic arthritis or psoriasis,” said Leah M. Howard, J.D., President and CEO of the National Psoriasis Foundation. “We welcome the introduction of this additional formulation to expand the array of options available to our community.”

    Related Posts

    U.S. Hotel Construction Shrinks Again for Ninth Consecutive Month

    October 23, 2025

    AWS Restores Services After Major Cloud Outage Disrupts Users Globally

    October 22, 2025

    Palantir, Snowflake’s Big AI Data Partnership Fails to Win Over Investors

    October 17, 2025

    China Blamed for Major Breach at U.S. Cybersecurity Giant F5, Reports Bloomberg

    October 17, 2025

    Pfizer CEO Urges US Pharma Industry to Partner with China

    October 16, 2025

    Stadler Boosts Production Speed with Panasonic’s Automated Robot Welding System

    October 15, 2025
    Top Posts

    U.S. Hotel Construction Shrinks Again for Ninth Consecutive Month

    October 23, 2025

    AWS Restores Services After Major Cloud Outage Disrupts Users Globally

    October 22, 2025

    Palantir, Snowflake’s Big AI Data Partnership Fails to Win Over Investors

    October 17, 2025
    Don't Miss

    U.S. Hotel Construction Shrinks Again for Ninth Consecutive Month

    October 23, 2025

    Key Highlights The U.S. hotel construction pipeline contracted for the ninth consecutive month, underscoring the…

    AWS Restores Services After Major Cloud Outage Disrupts Users Globally

    October 22, 2025

    Palantir, Snowflake’s Big AI Data Partnership Fails to Win Over Investors

    October 17, 2025

    China Blamed for Major Breach at U.S. Cybersecurity Giant F5, Reports Bloomberg

    October 17, 2025
    Stay In Touch
    • Facebook
    • Twitter
    • Instagram
    • LinkedIn
    About Us
    About Us

    Business Leaders Review is a global print and digital monthly and yearly magazine, which provides a platform to showcase business/tech leaders and their company’s profile from various sectors. Our aim is to publish the c-suite leaders stories.

    We are helping the leaders & readers to showcase their ideas and innovations to the business and tech world in this current market situation along with their awards and achievements. Doing so we hope to leverage thousands of businesses and personnel around the globe.

    Most Popular

    U.S. Hotel Construction Shrinks Again for Ninth Consecutive Month

    AWS Restores Services After Major Cloud Outage Disrupts Users Globally

    Palantir, Snowflake’s Big AI Data Partnership Fails to Win Over Investors

    Latest Magazines
    Facebook X (Twitter) LinkedIn Instagram
    • Home
    • Our Clients
    • TECHNLOGY NEWS
    • Industry News
    • Contact Us
    • Privacy Policy
    • Reprints and Permissions
    © 2021-2025 Business Leaders Review LLC | All Rights Reserved | Empowering Communication Globally

    Type above and press Enter to search. Press Esc to cancel.